EliteImmune is a pioneering biotechnology company dedicated to developing innovative antibody-based drugs for the targeted therapy and prevention of infectious diseases. Utilizing its proprietary platforms, CellProbe™ and CellSeq™, EliteImmune specializes in identifying naturally occurring antibody leads through advanced high-resolution and high-throughput screening of B cell repertoires from elite donors. The company boasts a strong pipeline of unique antibodies that exhibit exceptional selectivity, affinity, and therapeutic efficacy against a variety of pathogens.

Their product offerings include solutions for notable infectious agents such as filoviruses, respiratory syncytial virus, coronaviruses, arenaviruses, and Staphylococcus. In addition to these products, EliteImmune provides comprehensive services in antibody discovery, immunoglobulin sequencing analysis, antiviral assays, and virus production. Positioned to expand its influence into immuno-oncology and aging-related therapies, EliteImmune actively seeks strategic partnerships with pharmaceutical and biotech firms for collaborative development and licensing opportunities